Ignite Creation Date:
2025-12-24 @ 10:17 PM
Ignite Modification Date:
2025-12-31 @ 12:05 AM
Study NCT ID:
NCT00913835
Status:
COMPLETED
Last Update Posted:
2019-09-26
First Post:
2009-06-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-06
Start Date Type:
None
Primary Completion Date:
2011-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-02
Completion Date Type:
ACTUAL
First Submit Date:
2009-06-02
First Submit QC Date:
None
Study First Post Date:
2009-06-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-11-18
Results First Submit QC Date:
None
Results First Post Date:
2017-04-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2011-09-26
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2019-09-10
Last Update Post Date:
2019-09-26
Last Update Post Date Type:
ACTUAL